Medical News Today
Draft guidance from NICE on the use of ranibizumab (Lucentis) and pegaptanib (Macugen) has been issued for public consultation recently. The guidance recommends the use of Lucentis for about 20% of patients with wet age-related macular degeneration, a condition which causes sight loss and blindness.